Pretreatment with cilnidipine attenuates hypoxia/reoxygenation injury in HL-1 cardiomyocytes through enhanced NO production and action potential shortening.
Action Potentials
/ drug effects
Animals
Apoptosis
/ drug effects
Calcium Channel Blockers
/ pharmacology
Cell Line
Cell Survival
/ drug effects
Dihydropyridines
/ pharmacology
Gene Knockdown Techniques
Hypoxia
/ metabolism
Mice
Myocytes, Cardiac
/ drug effects
Nitric Oxide
/ metabolism
Nitric Oxide Synthase Type III
/ genetics
Phosphorylation
/ drug effects
RNA, Small Interfering
Rats
Action potential
Cilnidipine
Ischemia reperfusion
NO
eNOS
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
30
07
2019
accepted:
03
12
2019
revised:
15
11
2019
pubmed:
17
1
2020
medline:
19
8
2021
entrez:
17
1
2020
Statut:
ppublish
Résumé
Myocardial ischemia/reperfusion injury worsens in the absence of nitric oxide synthase (NOS). Cilnidipine, a Ca
Identifiants
pubmed: 31942044
doi: 10.1038/s41440-019-0391-7
pii: 10.1038/s41440-019-0391-7
doi:
Substances chimiques
Calcium Channel Blockers
0
Dihydropyridines
0
RNA, Small Interfering
0
Nitric Oxide
31C4KY9ESH
cilnidipine
97T5AZ1JIP
Nitric Oxide Synthase Type III
EC 1.14.13.39
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-388Commentaires et corrections
Type : CommentIn
Références
Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366:54–63.
Spath NB, Mills NL, Cruden NL. Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials. Future Cardiol. 2016;12:655–72.
Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J. 2017;38:935–41.
Prieto-Moure B, Lloris-Carsí JM, Barrios-Pitarque C, Toledo-Pereyra LH, Lajara-Romance JM, Berda-Antolí M, et al. Pharmacology of Ischemia Reperfusion. Translational research considerations. J Investig Surg. 2016;29:234–49.
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–36.
Kunst G, Klein AA. Peri-operative anaesthetic myocardial preconditioning and protection - cellular mechanisms and clinical relevance in cardiac anaesthesia. Anaesthesia. 2015;70:467–82.
Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;61:402–13.
Cohen MV, Yang XM, Downey JM. Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res. 2006;70:231–9.
Bice JS, Jones BR, Chamberlain GR, Baxter GF. Nitric oxide treatments as adjuncts to reperfusion in acute myocardial infarction: a systematic review of experimental and clinical studies. Basic Res Cardiol. 2016;111:23.
Arroyo-Martínez EA, Meaney A, Gutiérrez-Salmeán G, Rivera-Capello JM, GonzálezCoronado V, Alcocer-Chauvet A, et al. Is Local Nitric Oxide Availability Responsible for Myocardial Salvage after Remote Preconditioning? Arq Bras Cardiol. 2016;107:154–62.
Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd’Heuil D, et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol. 1999;276:H1567–H1573.
Elrod JW, Greer JJ, Bryan NS, Langston W, Szot JF, Gebregzlabher H, et al. Cardiomyocyte-specific overexpression of NO synthase-3 protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol. 2006;26:1517–23.
Tominaga M, Ohya Y, Tsukashima A, Kobayashi K, Takata Y, Koga T, et al. Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc Drugs Ther. 1997;11:43–48.
Kobayashi N, Mori Y, Mita S, Nakano S, Kobayashi T, Tsubokou Y, et al. Effects of cilnidipine on nitric oxide and endothelin-1 expression and extracellular signal-regulated kinase in hypertensive rats. Eur J Pharm. 2001;422:149–57.
Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E, et al. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol. 2008;384:896–907.
Tanno S, Yamamoto K, Kurata Y, Adachi M, Inoue Y, Otani N, et al. Protective effects of topiroxostat on an ischemia-reperfusion model of rat hearts. Circ J. 2018;82:1101–11.
Bahrudin U, Morikawa K, Takeuchi A, Kurata Y, Miake J, Mizuta E, et al. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. J Mol Biol. 2011;413:857–78.
Courtemanche M, Ramirez RJ, Nattel S, Am J. Physiol. Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol. 1998;275:H301–H321. https://doi.org/10.1152/ajpheart.1998.275.1.H301
doi: 10.1152/ajpheart.1998.275.1.H301
Brutsaert DL. Cardiac endothelial-myocardial signaling: Its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003;83:59–115.
Boveris A, Costa LE, Poderoso JJ, Carreras MC, Cadenas E. Regulation of mitochondrial respiration by oxygen and nitric oxide. Ann N Y Acad Sci. 2000;899:121–35.
Ding Y, Vaziri ND. Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension. 1998;32:718–23.
Ishii M. Pharmacokinetics study of FRC-8653 (Cilnidipine). Jpn Pharm Ther. 1993;21:43–52.
Jiang J, Cyr D, Babbitt RW, Sessa WC, Patterson C. Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the cochaperone/ubiquitin ligase CHIP. J Biol Chem. 2003;278:49332–41.
Nedvetsky PI, Sessa WC, Schmidt HH. There’s NO binding like NOS binding: protein-protein interactions in NO/cGMP signaling. Proc Natl Acad Sci USA. 2002;99:16510–2.
Smolenski PA, Muller H, Kronich P, Kugler P, Walter U, Schnitzer JE, et al. Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat Cell Biol. 2002;4:307–11.
Lee YM, Cheng PY, Chen SY, Chung MT, Sheu JR. Wogonin suppresses arrhythmias, inflammatory responses, and apoptosis induced by myocardial ischemia/reperfusion in rats. J Cardiovasc Pharm. 2011;58:133–42.
Li J, Zhang H, Zhang C. Role of inflammation in the regulation of coronary blood flow in ischemia and reperfusion: Mechanisms and therapeutic implications. J Mol Cell Cardiol. 2012;52:865–72.
Gottlieb RA. Cell death pathways in acute ischemia/reperfusion injury. J Cardiovasc Pharm Ther. 2011;16:233–8.
Koenitzer JR, Freeman BA. Redox signaling in inflammation: Interactions of endogenous electrophiles and mitochondria in cardiovascular disease. Ann N Y Acad Sci. 2010;1203:45–52.
Szewczyk A, Jarmuszkiewicz W, Koziel A, Sobieraj I, Nobik W, Lukasiak A, et al. Mitochondrial mechanisms of endothelial dysfunction. Pharm Rep. 2015;67:704–10.
Zhang P, Lu Y, Yu D, Zhang D, Hu W. Trap1 provides protection against myocardial ischemia-reperfusion injury by ameliorating mitochondrial dysfunction. Cell Physiol Biochem. 2015;36:2072–82.
Pike MM, Luo CS, Clark MD, Kirk KA, Kitakaze M, Madden MC, et al. Nmr measurements of na+ and cellular energy in ischemic rat heart: Role of na(+)-h+ exchange. Am J Physiol. 1993;265:2017–26.
Smith MA, Schnellmann RG. Calpains, mitochondria, and apoptosis. Cardiovasc Res. 2012;96:32–37.
Zhang JY, Wu F, Gu XM, Jin ZX, Kong LH, Zhang Y, et al. The blockade of transmembrane cl(-) flux mitigates i/r-induced heart injury via the inhibition of calpain activity. Cell Physiol Biochem. 2015;35:2121–34.
Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ros-induced ros release: an update and review. Biochim Biophys Acta. 2006;1757:509–17.
Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983–92.
Cheng O, Ostrowski RP, Wu B, Liu W, Chen C, Zhang JH. Cyclooxygenase-2 mediates hyperbaric oxygen preconditioning in the rat model of transient global cerebral ischemia. Stroke. 2011;42:484–90.
Thandroyen FT, McCarthy J, Burton KP, Opie LH. Ryanodine and caffeine prevent ventricular arrhythmias during acute myocardial ischemia and reperfusion in rat heart. Circ Res. 1988;62:306–14.
Zhao CY, Greenstein JL, Winslow RL. Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation. J Mol Cell Cardiol. 2017;106:29–44.
Takahara A, Nakamura Y, Wagatsuma H, Aritomi S, Nakayama A, Satoh Y, et al. Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br J Pharm. 2009;158:1366–74.
Hayashi T, Yamaguchi T, Sakakibara Y, Taguchi K, Maeda M, Kuzuya M, et al. eNOS-dependent antisenscence effect of a calcium channel blocker in human endothelial cells. PLoS ONE. 2014;9:e88391.
Matsubara M, Yao K, Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release. Pharm Res. 2006;53:35–43.
Fan L, Yang Q, Xiao XQ, Grove KL, Huang Y, Chen ZW, et al. Dual actions of cilnidipine in human internal thoracic artery: inhibition of calcium channels and enhancement of endothelial nitric oxide synthase. J Thorac Cardiovasc Surg. 2011;141:1063–9.
Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron O. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res. 2006;71:478–85.